Business, energy, technology, markets and global industry news from Business News Today

Phase 1 trial

PharmaDeviceNews Phase 1 trial
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Pharma & Biotech

Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy

Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.

Read More
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up

KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.

Read More
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Pharma & Biotech

What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment

AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.

Read More
Pharma & Biotech

Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies

Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.

Read More
Pharma & Biotech

Scynexis expands SCY-247 program with IV SAD and MAD trial launch

SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.

Read More
Pharma & Biotech

Why MIRA Pharmaceuticals is targeting chemotherapy-induced nerve pain with Ketamir-2

Find out how MIRA Pharmaceuticals aims to transform CIPN care with Ketamir-2 and why regulators and investors are watching its 2026 development milestones.

Read More
Pharma & Biotech

How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs

Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.

Read More